Abstract: Chimeric antigen receptor T( CAR-T) cells have demonstrated promising results against hematological malignancies,b ut have encountered significant challenges in translation to solid tumors.T oo vercome these hurdles,w eh ave developed as witchable CAR-Tc ell platform in which the activity of the engineered cell is controlled by dosage of an antibody-based switch. Herein, we apply this approacht o Her2-expressing breast cancers by engineering switch molecules through site-specific incorporation of FITC or grafting of ap eptide neo-epitope (PNE) into the anti-Her2 antibody trastuzumab (clone 4D5). We demonstrate that both switch formats can be readily optimizedt or edirect CAR-T cells (specific for the corresponding FITC or PNE) to Her2-expressing tumor cells,and afforddose-titratable activation of CAR-T cells ex vivo and complete clearance of the tumor in rodent xenograft models.T his strategy mayf acilitate the application of immunotherapyt os olid tumors by affording comparable efficacy with improved safety owing to switchbased control of the CAR-T response.
Adoptive immunotherapy using chimeric antigen receptor T (CAR-T) cells is ap romising approach for cancer treatment. [1] [2] [3] Clinical trials have demonstrated marked antitumor responses for patients with hematological malignancies, including those who have failed conventional therapies. [4] [5] [6] [7] Despite these promising early results,s ignificant challenges still exist. Fore xample,l eukemia and lymphoma patients treated with CD19-specific CAR-T cells have suffered severe cytokine release syndrome (CRS) owing to the rapid activation and expansion of CAR-Tcells upon encountering CD19-positive cells,a nd developed long-term B-cell aplasia owing to the persistence of the CAR-T response. [4, 8, 9] Thetreatment of solid tumors has proven even more problematic due to ontarget, off-tumor activity of CAR-T cells that has resulted in damage to healthy tissue. [10] In other solid tumor trials,CARTc ells have demonstrated insufficient efficacy. [11, 12] Thus,i t has become increasingly appreciated that the treatment of solid tumors with CAR-T cell therapy requires robust methods for systematically optimizing and precisely controlling the engineered cells to provide an effective therapy with mitigated risks to the patient. One method that has been proposed is asafety switch that can eliminate engineered cells in the case of an adverse event. [13] However,t his strategy results in irreversible loss of therapeutic cells from circulation and does not solve the intrinsic lack of control associated with conventional CAR-T cell therapy.
To control CAR-T cell activation, we and others have previously developed antibody-based switch molecules that control the activation, antigen specificity,a nd phenotype of CAR-T cells by the formation of as witch-dependent immunological synapse. [14] [15] [16] This switchable CAR-T(sCAR-T) cell platform relies on asCAR that is specific for abio-orthogonal antigen (not present in normal tissue), and ar ecombinant antibody-based switch that confers tumor specificity and also contains the sCAR antigen. Thea ctivity of these sCAR-T cells is entirely dependent on the presence of the switch molecule.R ecently,w er eported the development of two sCAR platforms that utilized either semi-synthetic switches, generated by site-specific chemical conjugation of the targeting antibody with the small molecule fluorescein isothiocyanate (FITC), or fully recombinant switches constructed from genetic fusion of the targeting antibody with as hort peptide neo-epitope (PNE) derived from the GCN4 peptide sequence. [15, 16] sCAR-T cells redirected by either FITC-or PNE-tagged switches efficiently cleared CD19 + Nalm-6 tumors in murine xenograft models with reduced toxicity by virtue of the ability to titrate the sCAR-T cell response. Additionally,s CAR-T activity could be terminated by removal of the switch. Moreover,t his platform can allow one universal CAR-T cell to be redirected to target heterogeneous or resistant tumors with multiple distinct switches, which should further improve the effectiveness of this therapeutic modality. [15] [16] [17] [18] [19] Herein, we extend this methodology to target Her2-expressing breast cancer cells.T ogenerate anti-Her2 switches, the FITC or PNE peptide was introduced into the anti-Her2 antibody fragment Fab( clone 4D5) at defined sites in the variable or constant regions.T hese positions were chosen to vary the distance and orientation between the CARa nd tumor antigen to optimize the immunological synapse.For the FITC-based switches,abio-orthogonal genetically encoded unnatural amino acid was used to site-specifically conjugate FITC to 4D5 Fab. Briefly,amutant 4D5 Fabw ith aT AG nonsense codon at the desired sites was co-expressed in Escherichia coli (E. coli)w ith an orthogonal Methanococcus jannaschii-derived tRNA/aminoacyl-tRNAs ynthetase pair that selectively incorporates p-azidophenylalanine (pAzF) into proteins in response to the TAGc odon. Based on previous experiments,pAzF was individually incorporated at light chain residues (LG68X or LS202X) or heavy chain residues (HS75X or HK136X) to generate four monovalent switches ( Figure 1A) . [15] In addition, two bivalent switches were constructed with pAzF at both LG68X and HS75X, or LS202X and HK136X. To conjugate FITC to the Fab, alinkermodified FITC molecule containing ac yclooctyne group (BCN-PEG4-FITC) was attached through "Click" reaction [20, 21] (Supporting Information, Figure S1 ). Conjugation reactions proceeded to > 95 %c ompletion as determined by SDS-PAGEg el ( Figure S2 A) and mass spectrometry (MS; Figure S3 and Table S1 ).
To generate PNE switch molecules,w eg rafted the PNE peptide sequence to the N-or C-terminus of the 4D5 Fab heavy chain or light chains to create the light chain Nterminal (LCNT), light chain C-terminal (LCCT), heavy chain N-terminal (HCNT), or heavy chain C-terminal (HCCT) switches ( Figure 1A ). AG GGGS peptide linker was used to separate the peptide tag from the Fab. To create bivalent switches,the PNE was grafted onto either the N-or C-terminus of the heavy and light chains to create NTBV or CTBV,r espectively ( Figure 1A ). Proteins were expressed in HEK293 suspension cells and further purified to > 95 % homogeneity as confirmed by SDS-PAGEg el (Figure S2 B) . MS analysis confirmed that the PNE fusions were not subject to post-translational modification or proteolysis ( Figure S4 and Table S2 ). Theb inding affinity of all of the switches to SKBR3 (Her2 3 + ,c linical immunohistochemistry score), MDA-MB453 (Her2 2 +), MDA-MB231, MDA-MB435 (Her2 1 +), and MDA-MB468 (Her2 0) [22] cancer cells was assessed by flow cytometry.Asshown in Figure S5 , FITC-and PNE-based switches bound to Her2-expressing cancer cells to as imilar extent as wild-type 4D5 Fab ( Table S3 and S4) . Importantly,t hese switch molecules did not bind to MDA-MB468 (Her2-negative) cancer cells,confirming the specificity of the modified 4D5 Fab-based switches.
We have previously engineered sCARs using high affinity scFvs for FITC or the PNE [23, 24] in 4-1BB-based second generation CARb ackbones [25] ( Figure 1B ). Fort he PNE sCAR, we further showed that as hort 12 amino acid hinge region (which connects the scFv to the transmembrane domain), derived from ad imeric mutant (S228P) of the IgG4 hinge (IgG4m), afforded greater activity than al onger 45 amino acid CD8 hinge region that is used in many conventional CARc onstructs. [16] Therefore,f or both the FITC and PNE sCARs,w eg enerated constructs harboring both the IgG4m and CD8 hinges ( Figure 1B ). Comparable sCAR expression (transduction efficiency of~60 %) for all four of the constructs on the surface of Tcells was confirmed by flow cytometry,c onsistent with previous results. [15, 16] We then tested the ability of the sCAR-T cells with CD8 or IgG4m hinges to bind to their corresponding anti-Her2 switches.A ss hown in Figures S6 and S7 , all of the switches bound to their corresponding sCAR-T cells with similar affinities.T he wild-type 4D5 Fabo ra nu nrelated switch antibody,d id not bind to either sCAR-T cell, demonstrating the specificity of the sCARs for their respective tags (Figure S8) .
To determine the optimal switch/sCAR combination for targeting Her2-expressing cells,w em easured sCAR-T cell activation with monovalent (HS75X and LS202X for FITC; HCNT and LCCT for PNE) and bivalent (LG68X/HS75X and LS202X/HK136X for FITC;N TBV and CTBV for PNE) switches against breast cancer cells with varying levels of Positions of the four amino acids that were individuallym utated in separate constructs to encode pAzF-for FITC-conjugation are labeled with "F". The location of the two N-terminala nd two C-terminal positions that were grafted with the PNE (GCN4) are labeled with "P". The structure is derived from crystal structure Protein Data Bank ID 1N8Z. B) Representation of anti-FITC and anti-PNE (GCN4) sCARs containing the CD8 signaling sequence, corresponding scFv, extracellular hinge region (CD8 or IgG4m), CD8 transmembrane domain, 4-1BB co-stimulatory domain, and CD3z signalingdomain.
Her2 expression (Figures S9 and S10) . [22] In general, switches with FITC or PNE placed distal to the antigen-binding domain provided the greatest activation. This result is consistent with the membrane proximal epitope of the Her2-specific 4D5 Fabw hich likely requires extended distance between the sCAR-T cell and target cell to achieve an optimal synapse geometry (compared with switches against CD19 previously developed from the FMC63 Fab). Fora nti-FITC sCAR-T cells,t he bivalent LS202X/HK136X switch induced the highest sCAR-T activation, and this trend was most apparent on Her2 1 + cancer cells.A ss hown in Figure S9 , the CD8 hinge-based anti-FITC CAR-T cells afforded greater sCAR-T cell activation than the IgG4m hinge-based sCAR-T cells for all of the FITC switch designs, as determined by CD69/CD25 upregulation and inflammatory cytokine release (IL-2, IFN-g,and TNF-a). Interestingly, for anti-PNE sCAR-T cells the same hinge was not optimal for all representative PNE-based switches tested (Figure S10) . Thea nti-PNE sCAR harboring the CD8 hinge showed the greatest Tc ell activation and cytokine release when used with N-terminal (HCNT) PNE switches,but when the PNE was grafted onto the C-terminus (LCCT), the IgG4m hinge-based anti-PNE sCAR showed the best response.I na greement with the T-cell activation results, anti-FITC sCAR-T cells with the CD8 hinge were more cytotoxic than those with the IgG4m hinge (Figure 2A ), while anti-PNE sCAR-T cells with the IgG4m hinge were more cytotoxic than those with the CD8 hinge ( Figure 2B) . Notably,d ifferences in cytotoxicityf or CD8 versus IgG4m hinges were most apparent for Her2 1 + compared with Her2 3 + and Her2 2 + cells ( Figure S11 ). Thes mall number of immunological synapses formed by the low antigen density cells likely magnifies the requirement for optimal complex formation to produce efficient target cell cytotoxicity.C ytotoxicity by dose titration of all of the switch designs against Her2 1 + cells confirmed that the FITC LS202X/HK136X with anti-FITC CAR-T cells harboring CD8 hinge (EC 50 ranging from 2.9 AE 0.2 to 18.3 AE 2.4 pm ;F igure S12 and Table S5 ) and PNE CTBV with IgG4m-based anti-PNE CAR-T cells (EC 50 ranging from 2.0 AE 0.2 to 4.0 AE 0.7 pM; Figure S13 and Table S6 ) provided the greatest level of cytotoxicity.
To understand the basis for hinge preference in FITC-and PNE-based switches,w ee xamined the structural differences between FITC-and PNE-based switches.A ss hown in Figure S14 A, the LS202X and HK136X sites of FITC attachment are predicted to be approximately 24.4 a part, while the LCCT and HCCT grafting positions for the PNE are only 11.6 a part (Figure S14 B) . Because the linkers used for FITC small molecule conjugation (PEG4) and PNE grafting (GGGGS) are comparable in length, the differential activity may be due to the differences in the location of FITC conjugation sites relative to the PNE grafting location. To test this possibility,w ec onstructed ab ivalent FITC switch by conjugation to residues LG212X and HK221X, which are approximately 11.6 apart in the constant domain, and distal to the antigen binding region (Figure S14 C) . As shown in Figure S15 , the LG212X/HK221X FITC switch was more cytotoxic with the IgG4m hinge compared to the CD8 hinge in the FITC sCAR-T cell against Her2 1 + cells.Similarly,this Figure S16 ). This result is similar to that of the PNE-based CTBV switch with roughly the same geometry.C ollectively, these results indicate that concurrent design of the sCAR hinge and switch labeling sites is required to achieve the optimal distance and orientation for sCAR-T cell activation.
We next compared the in vitro cytotoxicityofthe optimal switch/sCAR pair with that of conventional anti-Her2 CAR. The4D5 scFv and CD8 hinge were used for the conventional anti-Her2 CAR, as previously reported. [26] Fort his experiment, 50 pm of the FITC LS202X/HK136X or PNE CTBV switch was used with the CD8 hinge FITC CAR or the IgG4m hinge CAR, respectively.A ss hown in Figure S17 , sCAR-T cells killed Her2 cancer cells with comparable efficacytothe conventional CAR-Her2 across all E:Tr atios tested. Both sCAR-T cells and conventional CAR-T cells showed good selectivity for Her2 cells with only minor cytotoxicity towards Her2 0MDA-MB468 cells.
To test the in vivo antitumor activity of each optimized sCAR-T,wefirst examined them in mouse xenograft models using Her2 3 + (HCC1954) and Her2 2 + (MDA-MB453) breast cancer tumors.T umor cells (5 10 6 )w ere inoculated subcutaneously in the right flank of NSG mice and solid tumors were grown until palpable (~300 mm 3 ). Theh alf-life of Fabs in mice is approximately 1-2 h. [27] However,inMDA-MB435/Her2 tumor-bearing mice,w eo bserved tumor distribution of IRDye800-Fab up to 72 hp ost intravenous (i.v.) injection, indicating excellent tumor residence of the relatively small Fabmolecule ( Figure S18 ). On day 10, mice were infused i.v.with 30 10 6 anti-FITC or anti-PNE sCAR-T cells, followed by i.v.injection of the corresponding switches every other day at 0.5 mg kg À1 for 14 days (total of 7i njections). Separately,control groups of sCAR-T cell-treated mice were dosed with wild-type 4D5 Fab. Thec onventional anti-Her2 CAR-T was included as apositive control. Tu mor growth was monitored for 50 days.A sshown in Figure 3A and 3B,b oth conventional and sCAR-T cells exhibited comparable tumor regression kinetics and completely eliminated both Her2 3 + and 2 + tumors by day 25;norelapse was observed during the course of the study.T reatment of sCAR-T cells with wild-type 4D5 Fabhad no effect on tumor growth. To test activity with lower antigen density Her2 1 + tumors,weused an orthotopic xenograft model with MDA-MB231 cells.I nt his model, 5 10 6 tumor cells were implanted into the right fourth mammary fat pad of female NSG mice to generate tumors.T en days after tumor implantation, treatment was started with the same dosing and schedule as the Her2 3 + and 2 + models described above.Asshown in Figure 3C ,sCAR-T cells fully eradicated Her2 1 + tumors by day 30, and no tumor relapse occurred during the 50 days of observation. Thek inetics of tumor clearance were comparable to that of conventional anti-Her2 CAR-T cells.T hese results show that sCAR-T cells constructed with different designs can specifically target and eliminate Her2-expressing tumors with comparable efficacy to ac onventional CAR-T approach. Although additional studies are required to determine the optimal dosing regimen, tumor distribution, persistence,a nd other factors that affect CAR-T cell safety and efficacy, we believe these studies will facilitate the application of CAR-T therapy to solid tumors for which monoclonal antibody or antibody-drug conjugate therapies are not effective.
